
Results Driven.
Trusted Advisors.

Alloush LLP is a corporate healthcare advisory firm strategically located in Washington, DC. The firm also has offices in New York and Boston and alliances with firms around the globe. Our main focus is in the biotechnology and pharmaceutical industry with a strong emphasis on emerging growth companies working on the development and commercialization of innovative products and technologies.
We strive to achieve a common goal with our clients - maximize growth while focusing on cost effective solutions for clients of all sizes and stages. Whether it comes to regulatory and compliance, commercial operations, business acquisitions or private equity, we remain aligned with our clients interests, as well as on the cutting edge of new developments in healthcare, business, and technology to accelerate our clients place in the market. We understand the complexities of securing funding, safeguarding intellectual property, establishing strategic partnerships, bringing new products to market, opening up new revenue streams, and protecting existing product lines.
Clients consider us as "go to advisors" for a multitude of matters based on of our level of expertise, attentiveness, and focus on cost effectiveness. We pride ourselves on being a client centric firm. For the last decade, this approach has allowed us to maintain the attention to detail needed while best serving our clients needs. And this philosophy is how our firm is able to achieve growth and success while building lasting business relationships.
About our Firm
Featured Articles

Intellectual Property
Amgen's Biosimilar IP Win Was Wrong, Hospira Tells Fed. Circ.
Read the article
Eli Lilly throws SCOTUS hail mary in Cialis patent infringement fight
Read the article
Incyte's faithful Jakafi—and its sales force—are ready to roll with new indication
Read the article
‘One-and-done’ for new drugs could cut patent thickets and boost generic competition
Read the article

Mergers & Acquisitions
Pharma Catches Another Case Of M&A Fever
Read the article
What M&A Looks Like During the Pandemic
Read the article
Mereo BioPharma to merge with OncoMed Pharmaceuticals
Read the article
Merck Buys Tilos for Up to $773 Million to Expand Oncology Pipeline
Read the article
Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal
Read the article
